Skip to Main Content
Skip Nav Destination


Dinutuximab

Basics

Name

Dinutuximab

Pronunciation

(din ue TUX i mab)

Brand Names: US

  • Unituxin

Therapeutic Category

  • Antineoplastic Agent, Anti-GD2
  • Antineoplastic Agent, Monoclonal Antibody

Medication Safety Issues

Sound-alike/look-alike issues:

Dinutuximab may be confused with daratumumab, denosumab, dinutuximab beta (available internationally), dostarlimab, durvalumab, isatuximab, loncastuximab tesirine, margetuximab, obinutuzumab, rituximab.

High-alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (chemotherapeutic agent, parenteral and oral) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care, Community/Ambulatory Care, and Long-Term Care Settings).

This item requires a subscription. For full access to this content, please log in to an existing user account or purchase an individual subscription. If you have an active subscription and appear logged in (your name appears in the upper right corner), but you cannot access content, please click the “Log Out” option under your name and log back in.
Close Modal

or Create an Account

Close Modal
Close Modal